Halozyme Therapeutics, Inc. · Biotechnology

HALOHalozyme Therapeutics, Inc.

Reports 2026-11-09 · MonReaction day 11-10upcoming

Before the print · expectations18 days to the print

Street consensus

$2.40EPS
$501MRevenue

No past prints on file yet.

What the record doesn't tell you

Which way does HALO go on 11‑09?

  • Model lean for 11-09, and the evidence behind it
  • Move band, P10 – P90
  • Last 8 prints, quarter by quarter
  • Peers that already reported, and how they traded
Start 30-day free trialFull access · no card requiredHave an account? Sign inThe lean freezes the night before the print.

The print · 8-K and callupcoming · 2026-11-09

Revenue—
est. $501M
EPS—
est. $2.40
Guidance—read from the 8-K once filed

Lean, stance and evidence on this page are model outputs, not investment advice. Trade at your own risk. Disclaimer →

Halozyme Therapeutics earnings preview: what the record says

Halozyme Therapeutics (HALO) is scheduled to report earnings on Nov 9, 2026. The consensus estimate calls for EPS of $2.40 on revenue of $501M.

Figures come from NextPick's earnings-reaction ledger and the options market. Not investment advice.

HALO earnings: key questions

When is HALO's next earnings date?

Halozyme Therapeutics is scheduled to report on Nov 9, 2026.

What are HALO's earnings expectations?

Analysts expect EPS of $2.40 on revenue of $501M for the quarter.